Clinical Trial

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 12, 2024 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-28.
Trial Details
NCT Number NCT06198868
Lead Sponsor Jiangsu Cancer Institute & Hospital
Conditions Non-small Cell Lung Cancer
Enrollment 60 participants
Start Date 2024-02-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-01-12